Drug Profile
Research programme: type 2 diabetes mellitus biotherapeutics - Precigen Inc/Janssen Pharmaceutica
Latest Information Update: 11 Feb 2020
Price :
$50
*
At a glance
- Originator Intrexon Corporation; Janssen Pharmaceutica
- Developer Janssen Pharmaceutica; Precigen Inc
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Metabolic disorders; Obesity; Type 2 diabetes mellitus
Most Recent Events
- 03 Feb 2020 Intrexon Corporation is now called Precigen Inc
- 28 Jan 2020 No recent reports of development identified for research development in Metabolic-disorders in USA (PO)
- 28 Jan 2020 No recent reports of development identified for research development in Obesity in USA (PO)